User login
Key clinical point: Patients who received dupilumab for atopic dermatitis (AD) had moderate-to-severe disease, long medical history, and high prevalence of coexisting type 2 inflammatory diseases.
Major finding: A majority of patients (66.6%) were diagnosed with AD in childhood, and most patients presented with bordering moderate-to-severe AD (Eczema Area and Severity Index > 21), high prevalence of pruritus (99.6%), and coexisting atopic and type 2 inflammatory diseases (51.8%).
Study details: Findings are from an analysis of PROLEAD, a national, multicenter, prospective, non-interventional study, including 817 patients with moderate-to-severe AD who received dupilumab.
Disclosures: This study was funded by Sanofi. Three authors declared being employees of or holding stocks in Sanofi. The other authors reported ties with several sources, including Sanofi.
Source: Thaci D et al. Dupilumab treatment of atopic dermatitis in routine clinical care: Baseline characteristics of patients in the PROLEAD prospective, observational study. Dermatol Ther (Heidelb). 2022;12(9):2145-2160 (Aug 19). Doi: 10.1007/s13555-022-00791-1
Key clinical point: Patients who received dupilumab for atopic dermatitis (AD) had moderate-to-severe disease, long medical history, and high prevalence of coexisting type 2 inflammatory diseases.
Major finding: A majority of patients (66.6%) were diagnosed with AD in childhood, and most patients presented with bordering moderate-to-severe AD (Eczema Area and Severity Index > 21), high prevalence of pruritus (99.6%), and coexisting atopic and type 2 inflammatory diseases (51.8%).
Study details: Findings are from an analysis of PROLEAD, a national, multicenter, prospective, non-interventional study, including 817 patients with moderate-to-severe AD who received dupilumab.
Disclosures: This study was funded by Sanofi. Three authors declared being employees of or holding stocks in Sanofi. The other authors reported ties with several sources, including Sanofi.
Source: Thaci D et al. Dupilumab treatment of atopic dermatitis in routine clinical care: Baseline characteristics of patients in the PROLEAD prospective, observational study. Dermatol Ther (Heidelb). 2022;12(9):2145-2160 (Aug 19). Doi: 10.1007/s13555-022-00791-1
Key clinical point: Patients who received dupilumab for atopic dermatitis (AD) had moderate-to-severe disease, long medical history, and high prevalence of coexisting type 2 inflammatory diseases.
Major finding: A majority of patients (66.6%) were diagnosed with AD in childhood, and most patients presented with bordering moderate-to-severe AD (Eczema Area and Severity Index > 21), high prevalence of pruritus (99.6%), and coexisting atopic and type 2 inflammatory diseases (51.8%).
Study details: Findings are from an analysis of PROLEAD, a national, multicenter, prospective, non-interventional study, including 817 patients with moderate-to-severe AD who received dupilumab.
Disclosures: This study was funded by Sanofi. Three authors declared being employees of or holding stocks in Sanofi. The other authors reported ties with several sources, including Sanofi.
Source: Thaci D et al. Dupilumab treatment of atopic dermatitis in routine clinical care: Baseline characteristics of patients in the PROLEAD prospective, observational study. Dermatol Ther (Heidelb). 2022;12(9):2145-2160 (Aug 19). Doi: 10.1007/s13555-022-00791-1